Related references
Note: Only part of the references are listed.A randomized phase 2 trial of azacitidine with or without durvalumab as first-line therapy for older patients with AML
Amer M. Zeidan et al.
BLOOD ADVANCES (2022)
Flotetuzumab as salvage immunotherapy for refractory acute myeloid leukemia
Geoffrey L. Uy et al.
BLOOD (2021)
A Phase 2, Open-Label, Multiarm, Multicenter Study to Evaluate Magrolimab Combined with Antileukemia Therapies for First-Line, Relapsed/Refractory, or Maintenance Treatment of Acute Myeloid Leukemia
Paresh Vyas et al.
BLOOD (2021)
A Phase 3, Randomized, Open-Label Study Evaluating the Safety and Efficacy of Magrolimab in Combination with Azacitidine in Previously Untreated Patients with TP53-Mutant Acute Myeloid Leukemia
Naval Daver et al.
BLOOD (2021)
Phase I/II Study of Azacitidine (AZA) with Venetoclax (VEN) and Magrolimab (Magro) in Patients (pts) with Newly Diagnosed Older/Unfit or High-Risk Acute Myeloid Leukemia (AML) and Relapsed/Refractory (R/R) AML
Naval Daver et al.
BLOOD (2021)
Proof of concept for a rapidly switchable universal CAR-T platform with UniCAR-T-CD123 in relapsed/refractory AML
Martin Wermke et al.
BLOOD (2021)
Autologous CD33-CAR-T cells for treatment of relapsed/refractory acute myelogenous leukemia
Francesco Paolo Tambaro et al.
LEUKEMIA (2021)
A phase 1b/2 study of azacitidine with PD-L1 antibody avelumab in relapsed/refractory acute myeloid leukemia
Kapil Saxena et al.
CANCER (2021)
The landscape of bispecific T cell engager in cancer treatment
Shujie Zhou et al.
BIOMARKER RESEARCH (2021)
Phase II Trial of Pembrolizumab after High-Dose Cytarabine in Relapsed/Refractory Acute Myeloid Leukemia
Joshua F. Zeidner et al.
BLOOD CANCER DISCOVERY (2021)
Mutational profile and benefit of gemtuzumab ozogamicin in acute myeloid leukemia
Elise Fournier et al.
BLOOD (2020)
Updated results from phase I dose-escalation study of AMG 330, a bispecific T-cell engager molecule, in patients with relapsed/refractory acute myeloid leukemia (R/R AML).
Farhad Ravandi et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
Characterization of clinical pharmacokinetics and exposure-response relationships of AMG 330, a bispecific CD33 T-cell engager antibody construct, in patients with relapsed/refractory AML.
Suresh K Agarwal et al.
JOURNAL OF CLINICAL ONCOLOGY (2020)
CAR T Cells for Acute Myeloid Leukemia: State of the Art and Future Directions
Sherly Mardiana et al.
FRONTIERS IN ONCOLOGY (2020)
Azacitidine and Venetoclax in Previously Untreated Acute Myeloid Leukemia
C. D. DiNardo et al.
NEW ENGLAND JOURNAL OF MEDICINE (2020)
Immune landscapes predict chemotherapy resistance and immunotherapy response in acute myeloid leukemia
Jayakumar Vadakekolathu et al.
SCIENCE TRANSLATIONAL MEDICINE (2020)
10-day decitabine with venetoclax for newly diagnosed intensive chemotherapy ineligible, and relapsed or refractory acute myeloid leukaemia: a single-centre, phase 2 trial
Courtney D. DiNardo et al.
LANCET HAEMATOLOGY (2020)
TP53 abnormalities correlate with immune infiltration and associate with response to flotetuzumab immunotherapy in AML
Jayakumar Vadakekolathu et al.
BLOOD ADVANCES (2020)
Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of Vibecotamab (XmAb14045), a CD123 x CD3 T Cell-Engaging Bispecific Antibody; Initial Results of a Phase 1 Study
Farhad Ravandi et al.
BLOOD (2020)
Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo plus Ipilimumab (Ipi) in Relapsed/Refractory (R/R) Acute Myeloid Leukemia: Clinical and Immune Biomarkers of Response
Naval Daver et al.
BLOOD (2020)
First Results from the Dose Escalation Segment of the Phase I Clinical Study Evaluating Cyad-02, an Optimized Non Gene-Edited Engineered NKG2D CAR T-Cell Product, in Relapsed or Refractory Acute Myeloid Leukemia and Myelodysplastic Syndrome Patients
Dries Deeren et al.
BLOOD (2020)
Gemtuzumab ozogamicin for de novo acute myeloid leukemia: final efficacy and safety updates from the open-label, phase III ALFA-0701 trial
Juliette Lambert et al.
HAEMATOLOGICA (2019)
Targeting Immune Signaling Checkpoints in Acute Myeloid Leukemia
Krzysztof Giannopoulos
JOURNAL OF CLINICAL MEDICINE (2019)
A Phase 1 Study of Flotetuzumab, a CD123 x CD3 DART® Protein, Combined with MGA012, an Anti-PD-1 Antibody, in Patients with Relapsed or Refractory Acute Myeloid Leukemia
Andrew H. Wei et al.
BLOOD (2019)
Flotetuzumab (FLZ), an Investigational CD123 x CD3 Bispecific Dart® Protein-Induced Clustering of CD3+T Cells and CD123+AML Cells in Bone Marrow Biopsies Is Associated with Response to Treatment in Primary Refractory AML Patients
John E. Godwin et al.
BLOOD (2019)
The Interplay Between the Genetic and Immune Landscapes of AML: Mechanisms and Implications for Risk Stratification and Therapy
Lourdes M. Mendez et al.
FRONTIERS IN ONCOLOGY (2019)
Venetoclax combined with decitabine or azacitidine in treatment-naive, elderly patients with acute myeloid leukemia
Courtney D. DiNardo et al.
BLOOD (2019)
Azacitidine (AZA) with Nivolumab (Nivo), and AZA with Nivo plus Ipilimumab (Ipi) in Relapsed/Refractory Acute Myeloid Leukemia: A Non-Randomized, Prospective, Phase 2 Study
Naval G. Daver et al.
BLOOD (2019)
Multi-Center Phase 2 Study of Pembroluzimab (Pembro) and Azacitidine ( AZA) in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML) and in Newly Diagnosed (≥65 Years) AML Patients
Ivana Gojo et al.
BLOOD (2019)
Mutated nucleophosmin 1 as immunotherapy target in acute myeloid leukemia
Dyantha van der Lee et al.
JOURNAL OF CLINICAL INVESTIGATION (2019)
Efficacy, Safety, and Biomarkers of Response to Azacitidine and Nivolumab in Relapsed/Refractory Acute Myeloid Leukemia: A Nonrandomized, Open-Label, Phase II Study
Naval Daver et al.
CANCER DISCOVERY (2019)
Long-Term Follow-up of CD19 CAR Therapy in Acute Lymphoblastic Leukemia
Jae H. Park et al.
NEW ENGLAND JOURNAL OF MEDICINE (2018)
Oncogenic JAK2V617F causes PD-L1 expression, mediating immune escape in myeloproliferative neoplasms
Alessandro Prestipino et al.
SCIENCE TRANSLATIONAL MEDICINE (2018)
Complete Responses in Relapsed/Refractory Acute Myeloid Leukemia (AML) Patients on a Weekly Dosing Schedule of XmAb14045, a CD123 x CD3 T Cell-Engaging Bispecific Antibody: Initial Results of a Phase 1 Study
Farhad Ravandi et al.
BLOOD (2018)
Phase 1 Cohort Expansion of Flotetuzumab, a CD123xCD3 Bispecific Dart® Protein in Patients with Relapsed/Refractory Acute Myeloid Leukemia (AML)
Geoffrey L. Uy et al.
BLOOD (2018)
Expression of CD33 is a predictive factor for effect of gemtuzumab ozogamicin at different doses in adult acute myeloid leukaemia
N. Khan et al.
LEUKEMIA (2017)
Exploiting natural killer group 2D receptors for CAR T-cell therapy
Benjamin Demoulin et al.
FUTURE ONCOLOGY (2017)
Mutant IDH1 regulates the tumor-associated immune system in gliomas
Nduka M. Amankulor et al.
GENES & DEVELOPMENT (2017)
Nivolumab as Programmed Death-1 (PD-1) Inhibitor for Targeted Immunotherapy in Tumor
Liting Guo et al.
JOURNAL OF CANCER (2017)
The level of blast CD33 expression positively impacts the effect of gemtuzumab ozogamicin in patients with acute myeloid leukemia
Guillaume Olombel et al.
BLOOD (2016)
The future of cancer treatment: immunomodulation, CARs and combination immunotherapy
Danny N. Khalil et al.
NATURE REVIEWS CLINICAL ONCOLOGY (2016)
IDH mutant gliomas escape natural killer cell immune surveillance by downregulation of NKG2D ligand expression
Xiaoran Zhang et al.
NEURO-ONCOLOGY (2016)
CD33 target validation and sustained depletion of AML blasts in long-term cultures by the bispecific T-cell-engaging antibody AMG 330
Christina Krupka et al.
BLOOD (2014)
Addition of gemtuzumab ozogamicin to induction chemotherapy in adult patients with acute myeloid leukaemia: a meta-analysis of individual patient data from randomised controlled trials
Robert K. Hills et al.
LANCET ONCOLOGY (2014)
Chimeric Antigen Receptor T Cells for Sustained Remissions in Leukemia
Shannon L. Maude et al.
NEW ENGLAND JOURNAL OF MEDICINE (2014)
Treating acute myeloid leukemia in older adults
Eunice S. Wang
HEMATOLOGY-AMERICAN SOCIETY OF HEMATOLOGY EDUCATION PROGRAM (2014)
CD 123 is a membrane biomarker and a therapeutic target in hematologic malignancies
Ugo Testa et al.
BIOMARKER RESEARCH (2014)
Immune responses against the mutated region of cytoplasmatic NPM1 might contribute to the favorable clinical outcome of AML patients with NPM1 mutations (NPM1mut)
Jochen Greiner et al.
BLOOD (2013)
TP53 alterations in acute myeloid leukemia with complex karyotype correlate with specific copy number alterations, monosomal karyotype, and dismal outcome
Frank G. Rueckner et al.
BLOOD (2012)
Mutated regions of nucleophosmin 1 elicit both CD4+ and CD8+ T-cell responses in patients with acute myeloid leukemia
Jochen Greiner et al.
BLOOD (2012)
Acute myeloid leukemia stem cells and CD33-targeted immunotherapy
Roland B. Walter et al.
BLOOD (2012)
The CD47-SIRPα pathway in cancer immune evasion and potential therapeutic implications
Mark P. Chao et al.
CURRENT OPINION IN IMMUNOLOGY (2012)
Addition of Gemtuzumab Ozogamicin to Induction Chemotherapy Improves Survival in Older Patients With Acute Myeloid Leukemia
Alan K. Burnett et al.
JOURNAL OF CLINICAL ONCOLOGY (2012)
Comprehensive Analysis of NKG2D Ligand Expression and Release in Leukemia: Implications for NKG2D-Mediated NK Cell Responses
Julia Hilpert et al.
JOURNAL OF IMMUNOLOGY (2012)
Effect of gemtuzumab ozogamicin on survival of adult patients with de-novo acute myeloid leukaemia (ALFA-0701): a randomised, open-label, phase 3 study
Sylvie Castaigne et al.
LANCET (2012)
AML1/RUNX1 functions as a cytoplasmic attenuator of NF-κB signaling in the repression of myeloid tumors
Masahiro Nakagawa et al.
BLOOD (2011)
Effector Cell Recruitment with Novel Fv-based Dual-affinity Re-targeting Protein Leads to Potent Tumor Cytolysis and in Vivo B-cell Depletion
Syd Johnson et al.
JOURNAL OF MOLECULAR BIOLOGY (2010)
Ligands for natural killer cell-activating receptors are expressed upon the maturation of normal myelomonocytic cells but at low levels in acute myeloid leukemias
P Nowbakht et al.
BLOOD (2005)
Gemtuzumab ozogamicin, a potent and selective anti-CD33 antibody-calicheamicin conjugate for treatment of acute myeloid leukemia
PR Hamann et al.
BIOCONJUGATE CHEMISTRY (2002)
Share Paper
